Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants.

This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants.

More information about the clinical trial can be found on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02472769).

Staffan Strömberg, Chief Executive Officer of  IBT, comments, "We are very excited to have started the study and to now have the first baby included. This is an important milestone in our development of this potentially life-saving new drug.”


For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm , Sweden

Phone: +46 8 410 145 55

info@ibtherapeutics.com

Infant Bacterial Therapeutics AB (“IBT”) is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infants. IBT’s current focus is on clinical development of IBP-9414, a drug candidate containing  Lactobacillus reuteri , in the prevention of necrotizing enterocolitis (“NEC”), a fatal disease that affects premature infants. IBT is listed on Nasdaq First North with Erik Penser Bankaktiebolag as Certified adviser.

www.ibtherapeutics.com

About Us

Infant Bacterial Therapeutics AB (“IBT”) is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infant. IBT’s current focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (“NEC”), a fatal disease that affects premature infants. IBT is listed on NASDAQ First North. www.ibtherapeutics.com

Subscribe